Patient iPSC-Derived Macrophages to Study Inborn Errors of the IFN-γ Responsive Pathway
Kathrin Haake,
Anna-Lena Neehus,
Theresa Buchegger,
Mark Philipp Kühnel,
Patrick Blank,
Friederike Philipp,
Carmen Oleaga-Quintas,
Ansgar Schulz,
Michael Grimley,
Ralph Goethe,
Danny Jonigk,
Ulrich Kalinke,
Stéphanie Boisson-Dupuis,
Jean-Laurent Casanova,
Jacinta Bustamante,
Nico Lachmann
Affiliations
Kathrin Haake
REBIRTH Cluster of Excellence, Institute of Experimental Hematology, Hannover Medical School (MHH), 30625 Hannover, Germany
Anna-Lena Neehus
REBIRTH Cluster of Excellence, Institute of Experimental Hematology, Hannover Medical School (MHH), 30625 Hannover, Germany
Theresa Buchegger
REBIRTH Cluster of Excellence, Institute of Experimental Hematology, Hannover Medical School (MHH), 30625 Hannover, Germany
Mark Philipp Kühnel
Institute of Pathology, Hannover Medical School (MHH), 30625 Hannover, Germany
Patrick Blank
REBIRTH Cluster of Excellence, Institute of Experimental Hematology, Hannover Medical School (MHH), 30625 Hannover, Germany
Friederike Philipp
REBIRTH Cluster of Excellence, Institute of Experimental Hematology, Hannover Medical School (MHH), 30625 Hannover, Germany
Carmen Oleaga-Quintas
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Inserm U1163, Necker Hospital for Sick Children, 75015 Paris, France
Ansgar Schulz
Department of Pediatrics, University Medical Center Ulm, 89081 Ulm, Germany
Michael Grimley
Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH 45229, USA
Ralph Goethe
Institute for Microbiology, University of Veterinary Medicine Hannover, 30625 Hannover, Germany
Danny Jonigk
Institute of Pathology, Hannover Medical School (MHH), 30625 Hannover, Germany
Ulrich Kalinke
Institute for Experimental Infection Research, TWINCORE, Centre for Experimental and Clinical Infection Research, A Joint Venture between The Helmholtz Centre for Infection Research, Braunschweig, and The Hannover Medical School, 30625 Hannover, Germany
Stéphanie Boisson-Dupuis
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Inserm U1163, Necker Hospital for Sick Children, 75015 Paris, France
Jean-Laurent Casanova
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Inserm U1163, Necker Hospital for Sick Children, 75015 Paris, France
Jacinta Bustamante
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Inserm U1163, Necker Hospital for Sick Children, 75015 Paris, France
Nico Lachmann
REBIRTH Cluster of Excellence, Institute of Experimental Hematology, Hannover Medical School (MHH), 30625 Hannover, Germany
Interferon γ (IFN-γ) was shown to be a macrophage activating factor already in 1984. Consistently, inborn errors of IFN-γ immunity underlie Mendelian Susceptibility to Mycobacterial Disease (MSMD). MSMD is characterized by genetic predisposition to disease caused by weakly virulent mycobacterial species. Paradoxically, macrophages from patients with MSMD were little tested. Here, we report a disease modeling platform for studying IFN-γ related pathologies using macrophages derived from patient specific induced pluripotent stem cells (iPSCs). We used iPSCs from patients with autosomal recessive complete- and partial IFN-γR2 deficiency, partial IFN-γR1 deficiency and complete STAT1 deficiency. Macrophages from all patient iPSCs showed normal morphology and IFN-γ-independent functionality like phagocytic uptake of bioparticles and internalization of cytokines. For the IFN-γ-dependent functionalities, we observed that the deficiencies played out at various stages of the IFN-γ pathway, with the complete IFN-γR2 and complete STAT1 deficient cells showing the most severe phenotypes, in terms of upregulation of surface markers and induction of downstream targets. Although iPSC-derived macrophages with partial IFN-γR1 and IFN-γR2 deficiency still showed residual induction of downstream targets, they did not reduce the mycobacterial growth when challenged with Bacillus Calmette−Guérin. Taken together, we report a disease modeling platform to study the role of macrophages in patients with inborn errors of IFN-γ immunity.